Status:
COMPLETED
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This single arm study will determine the effects of complete anemia correction in anemic patients with end-stage renal disease currently receiving suboptimal doses of NeoRecormon. Patients on dialysis...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- end-stage renal disease;
- on renal dialysis \>= 3 months;
- receiving NeoRecormon treatment \>= 3 months;
- Hb stable and \<105g/L, and LVMI \>160g/m2.
Exclusion
- unstable hypertension, myocardial infarction, unstable angina pectoris or risk of deep vein thrombosis in last 6 months;
- use of any ESA other than NeoRecormon;
- acute infection;
- use of iv NeoRecormon.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00413101
End Date
March 1 2008
Last Update
May 14 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novi Sad, Serbia, 21000